Click here for Analysts' Upgrades, Downgrades.
Editor's Note: Green and red arrows refer to intraday stock price movement.
NEW YORK (
added to Conviction Buy List at Goldman. Company has good earnings visibility over the next couple of years.
estimates, target upped at Goldman. AGCO estimates were boosted through 2012. Visibility is improving for demand in Western Europe. Buy rating and new $55 price target.
price target cut at Barclays to $59 from $61. Investing in ALGT is risky, outlook uncertain, Barclays said. Maintain Overweight rating.
target, estimates higher at Credit Suisse. AMAT price target raised by a dollar to $15. Strong sector view, Credit Suisse said. 2010 and 2011 EPS estimates raised to $0.87 and $1.25, respectively. Maintain Neutral rating.
target boosted at Oppenheimer to $57. Company is likely seeing higher sales, especially at Red Lobster.
price target higher at Barclays to $80 from $75. Building out commercial infrastructure ahead of the potentially significant Sapien launch, Barclays said. Maintain Overweight rating.
Health Management Associates
price target boosted at Barclays by a dollar to $11. HMA has shown continued signs of progress with better-than-expected revenue growth, Barclays said. Maintain Overweight rating.
US Airways Group
price target raised at Barclays by a dollar to $15. Supply and demand balance in the industry will improve in the coming years, Barclays said. Maintain Equal Weight rating.
target, estimate boosted at Barclays to $43 from $35 on stronger growth, Credit Suisse said. 2011 and 2012 EPS estimates increased to $3.56 and $3.69, respectively. Maintain Outperform rating.
target increased at Oppenheimer. OXY target was raised to $105, Oppenheimer said. Company recently boosted its dividend and should continue to generate steady cash flow.
target raised at Oppenheimer. Shares of PXD now seen reaching $96, according to Oppenheimer. Company can continue to outperform its peers, despite lower energy prices.
price target raised at Barclays. TSO price target increased to $20 from $16 after positive meeting with management, Barclays said. Maintain Equal Weight rating.
This article was written by a staff member of TheStreet.